![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 38, 35730-35737, September 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
¶
,
¶
From the Departments of
Anatomy and Cell Biology,
¶ Pharmacology and Toxicology, and ** Urology, Queen's
University, Kingston, Ontario K7L 3N6, Canada
Received for publication, May 8, 2002, and in revised form, June 25, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Tumor hypoxia is
associated with a poor prognosis for patients with various cancers,
often resulting in an increase in metastasis. Moreover, exposure to
hypoxia increases the ability of breast carcinoma cells to invade the
extracellular matrix, an important aspect of metastasis. Here, we
demonstrate that the hypoxic up-regulation of invasiveness is linked to
reduced nitric oxide signaling. Incubation of human breast carcinoma
cells in 0.5% versus 20% oxygen increased their in
vitro invasiveness and their expression of the urokinase receptor, an invasion-associated molecule. These effects of hypoxia were inhibited by nitric oxide-mimetic drugs; and in a manner similar
to hypoxia, pharmacological inhibition of nitric oxide synthesis
increased urokinase receptor expression. The nitric oxide signaling
pathway involves activation of soluble guanylyl cyclase (sGC)
and the subsequent activation of protein kinase G (PKG). Culture of
tumor cells under hypoxic conditions (0.5% versus 20%
oxygen) resulted in lower cGMP levels, an effect that could be
prevented by incubation with glyceryl trinitrate. Inhibition of sGC
activity with a selective blocker or with the heme biosynthesis inhibitor desferrioxamine increased urokinase receptor expression. These compounds also prevented the glyceryl trinitrate-mediated suppression of urokinase receptor expression in cells incubated under
hypoxic conditions. In contrast, direct activation of PKG using
8-bromo-cGMP prevented the hypoxia- and desferrioxamine-induced increases in urokinase receptor expression as well as the
hypoxia-mediated enhanced invasiveness. Further involvement of PKG in
the regulation of invasion-associated phenotypes was established using
a selective PKG inhibitor, which alone increased urokinase receptor
expression. These findings reveal that an important mechanism by which
hypoxia increases tumor cell invasiveness (and possibly metastasis)
requires inhibition of the nitric oxide signaling pathway
involving sGC and PKG activation.
Hypoxia in cancers is associated with resistance to
therapy and with increased tumor growth and metastatic potential.
Several studies have demonstrated that tumor cells exposed to hypoxia exhibit reduced sensitivity to radiation and drug therapy (1-3), increased ability to invade the extracellular matrix in
vitro (4, 5), and greater in vivo metastatic potential
(6, 7). Exposure of human MDA-MB-231 breast carcinoma cells to hypoxia
enhances their ability to invade the extracellular matrix (Matrigel), and this effect of hypoxia is linked to increased expression of the cell-surface urokinase plasminogen activator receptor
(uPAR)1 (4). Furthermore,
hypoxia has been shown to increase metastasis of human melanoma cells
transplanted into nude mice by up-regulating uPAR expression (8).
Recently, it was shown that a causal link between hypoxia and the
acquisition of resistance to chemotherapeutic agents is a reduction in
the production of endogenous nitric oxide (NO) by tumor cells (2). In
that study, the increase in drug resistance caused by hypoxia was
prevented by low concentrations of NO-mimetic drugs; and in a manner
similar to hypoxia, pharmacological inhibition of endogenous NO
production with an NO synthase inhibitor led to a drug resistance
phenotype. Those findings suggested that NO may play a function in the
regulation of tumor cell adaptive responses to alterations in local
oxygenation levels.
Nitric oxide is produced endogenously by the enzyme NO
synthase (9), and has been implicated in several biological processes such as gene regulation. For example, NO has been shown to activate AP-1 (activator
protein-1)-regulated genes via a pathway
dependent on cGMP production (10). Nitric oxide also modulates hypoxic gene expression. Studies have revealed that NO inhibits the hypoxic induction of erythropoietin, vascular endothelial growth factor, and
hypoxia-inducible factor-1 (HIF-1) (11-13).
Soluble guanylyl cyclase (sGC) is a well characterized receptor for NO.
This heterodimeric protein catalyzes the conversion of GTP to cGMP.
Nitric oxide binds to the heme moiety of sGC, thereby inducing
conformational changes that result in sGC activation. cGMP is, in turn,
a second messenger that amplifies NO signals to downstream effectors
(14). Elevated levels of cGMP have been negatively correlated with
vascular smooth muscle growth and have been shown to prevent platelet
aggregation as well as the adherence of neutrophils to endothelial
cells (15-17). Furthermore, there is also evidence that cGMP can
prevent the hypoxic up-regulation of vascular endothelial growth factor
expression (12).
Several proteins interact with cGMP and potentially
regulate gene expression and cell phenotype at various levels of the
signaling cascade. These include protein kinase G (PKG),
cGMP-activated phosphodiesterases, and cGMP-gated ion channels. Of
these, it is thought that PKG is responsible for the majority of the
cellular effects of cGMP. PKG is a serine/threonine kinase that is
activated following cGMP binding (18). Upon activation, PKG
phosphorylates many intracellular targets, often resulting in
alterations in gene expression. Based on the previous knowledge
that NO plays a role in the regulation of cellular adaptive responses
to hypoxia and given the importance of cGMP-dependent
signaling in the actions of NO, we sought to investigate the role of
sGC, cGMP, and PKG in the NO-mediated regulation of tumor cell invasion.
Materials--
Glyceryl trinitrate (GTN; Sabex, Boucherville,
Quebec, Canada) and sodium nitroprusside (SNP; Sigma) were used as
NO-mimetic drugs. N-Monomethyl-L-arginine
(L-NMMA; Calbiochem-Novabiochem) was used to inhibit
endogenous NO production. 3-Isobutyl-1-methylxanthine (Sigma) was used
to inhibit phosphodiesterase activity. Desferrioxamine mesylate (DFO;
Sigma) was used as an iron chelator and inhibitor of heme biosynthesis.
1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; Sigma) was used to selectively inhibit sGC. 8-Bromo-cGMP (8-Br-cGMP; Sigma) was used to activate PKG, and KT5823 (Calbiochem) was used to selectively inhibit PKG.
Cells--
The MDA-MB-231 cell line was maintained in monolayer
culture in RPMI 1640 medium (Invitrogen) supplemented with 5% fetal
bovine serum (Invitrogen) in a standard Sanyo CO2 incubator
(5% CO2 in air at 37 °C; Esbe Scientific, Markham,
Ontario, Canada). This is a metastatic breast cancer cell line that was
initially isolated in 1973 from a pleural effusion obtained from a
51-year-old patient (19).
Culture Conditions--
To establish hypoxic conditions, cells
were placed in airtight chambers (BellCo Biotechnology, Vineland, NJ)
that were flushed with a gas mixture of 5% CO2 and 95%
N2. Oxygen concentrations within these chambers were
maintained at 0.5% using Pro-Ox Model 110 O2 regulators
(BioSpherix, Redfield, NY) as described previously (2).
In Vitro Invasion Assays--
To determine the
effect of hypoxia and the NO signaling pathway on the invasiveness of
MDA-MB-231 cells, we used a previously described assay (4) that employs
reconstituted basement membrane (Matrigel®, Collaborative
Biomedical Products, Bedford, MA) as the substrate for invasion.
Briefly, Costar Transwell® plastic inserts with
a 6.5-mm diameter polycarbonate membrane (8-µm pore; Corning Costar
Corp., Cambridge, MA) were coated with 100 µl of a 1 mg/ml solution
of Matrigel diluted in serum-free culture medium, placed in the wells
of a 24-well tissue culture plate, and allowed to air-dry for ~12 h.
After reconstituting the Matrigel with serum-free medium, 5.0 × 104 cells in serum-containing medium were added to the
inserts. Following a 24-h incubation under either hypoxic or standard
conditions, in the absence or presence of drugs, cells on the surface
of the Matrigel-coated polycarbonate membrane (non-invading cells) were removed by scraping with a cotton swab. Cells that invaded the Matrigel
and the pores of the underlying membrane were fixed in Carnoy's
fixative (25% acetic acid and 75% methanol) and stained with 1%
toluidine blue in 1% sodium borate. Following several rinses in tap
water, the membranes were removed with a small scalpel blade, placed on
a microscope slide, and coverslipped. The "invasion index" was
determined by counting, under a microscope, the total number of stained
cells on the underside of the polycarbonate membranes. In a pilot
study, we determined that the rate of MDA-MB-231 cell proliferation is
identical at 1% versus 20% O2 for at least 48 h, thereby indicating that differences in cell numbers on the membranes at the end of the invasion assay are reflective of altered invasive ability alone.
Northern Blot Analysis--
Following incubation, total cellular
RNA from cells was isolated using a Gentra Purescript® RNA
isolation kit (Gentra Systems, Inc., Minneapolis, MN). The isolated RNA was subsequently separated by electrophoresis, transferred to a charged nylon membrane (Micron Separations, Westborough, MA), and
fixed with ultraviolet radiation using a UV cross-linker (Bio-Rad). The
membranes were prehybridized at 42 °C in a hybridization incubator
for ~1 h using prewarmed ULTRAhyb® hybridization
buffer (Ambion Inc., Austin, TX). They were then hybridized overnight
at 42 °C with a uPAR cDNA probe that was cloned in a Bluescript
plasmid vector and labeled with [32P]dCTP using an
Amersham Biosciences Oligolabelling kit. Following serial
washes, the membranes were used to expose Kodak X-Omat Blue
film. After 1-4 days, the film was developed and analyzed. The
density of the rRNA bands was used to normalize the amount of total RNA
loaded in each well.
Measurement of Guanylyl Cyclase Activity--
To
determine sGC activity, cellular cGMP levels were measured using a
commercially available enzyme-linked immunosorbent assay (STI-Signal
Transduction Products, San Clemente, CA). Briefly, cells were
cultured for 6 h in 20% or 0.5% O2 in the presence or absence of GTN (1 µM). 3-Isobutyl-1-methylxanthine
(500 µM) was included in the culture medium to inhibit
phosphodiesterase activity, thereby allowing for a measurable
accumulation of cGMP. Cells were subsequently extracted over ice in 1 ml of 6% trichloroacetic acid (BDH Laboratory Supplies, Poole,
England). The homogenate was then centrifuged at 13,000 × g for 10 min. The supernatant fraction was removed and
extracted five times with 2 ml of water-saturated diethyl ether (BDH
Laboratory Supplies). The cGMP contained in this fraction was
subsequently acetylated and measured using the enzyme-linked
immunosorbent assay kit.
Western Blot Analysis of uPAR and sGC--
Following incubation,
cells were lysed in 40 mM HEPES (pH 7.2), 100 mM NaCl, 20% glycerol, 0.1 mM EDTA (pH 8.0),
0.2% Triton X-100, 1 mM dithiothreitol, and 2 mM phenylmethylsulfonyl fluoride. The lysates were
homogenized, followed by DNA shearing (10 times with a
25 Data Analysis and Statistical Methods--
X-ray films of
Northern and Western blot experiments were scanned and analyzed using a
SigmaGel densitometry software package (SPSS Inc., Chicago, IL). Data
are presented as means ± S.D. Statistical analyses were performed
using the StatView statistical software package (Abacus Concepts,
Inc., Berkley, CA). Statistical significance was determined
using one-way analysis of variance, followed by Fisher's post hoc
analysis. Student's t test was used when only two sets of
data were compared. All statistical tests were two-sided, and
differences were considered statistically significant at
p < 0.05.
Effect of NO-mimetic Drugs on the Hypoxic Up-regulation
of in Vitro Invasion and Expression of uPAR--
As shown in Fig.
1, although hypoxia increased the
in vitro invasiveness of MDA-MB-231 breast carcinoma cells
by >5-fold, this effect of hypoxia was prevented by concomitant
treatment with low concentrations of two different NO-mimetic drugs,
GTN (1 pM and 0.1 µM; p < 0.002 and 0.001, respectively; one-way analysis of variance, followed
by Fisher's test) and SNP (0.1 nM; p < 0.001), administered at the beginning of the 24-h invasion assay.
In our previous study (4), we showed that the hypoxic
up-regulation of invasiveness is accompanied by increased uPAR
expression and that a blocking anti-uPAR antibody could prevent the
hypoxic up-regulation of invasiveness, thereby establishing a causal
link between uPAR expression and hypoxia-induced invasion. In the
present study, culture of MDA-MB-231 cells in 0.5% O2 for
24 h also resulted in up to 3.5-fold increases (p < 0.0001) in uPAR protein levels (Figs.
2A and 5B) and up
to 5-fold increases (p < 0.0002) in uPAR mRNA
levels (Figs. 2C, 4A, and 5A).
Moreover, administration of single doses of GTN (1 pM, 1 nM, and 0.1 µM) to cells incubated for
24 h in 0.5% O2 was sufficient to prevent the
up-regulation of uPAR protein expression (p < 0.004, 0.005, and 0.001 for each concentration of GTN, respectively) (Fig.
2A). Similarly, the hypoxia-mediated increase in uPAR
mRNA levels was also inhibited when a low concentration of GTN (1 pM) was used (p < 0.001) (Fig. 2C).
Effect of NO Synthase Inhibition on uPAR Protein and mRNA
Levels--
As demonstrated in a previous study, MDA-MB-231 cells
express all three isoforms of NO synthase (2). To assess whether endogenous NO inhibits uPAR expression, NO synthesis in MDA-MB-231 cells was blocked by incubation with the NO synthase inhibitor L-NMMA (0.5 µM). In a manner characteristic
of cells exposed to hypoxia, a 24-h incubation with a single dose of
L-NMMA resulted in an overall 50% increase
(p < 0.004) in uPAR protein levels (Fig.
2B) and a 2.8-fold increase (p < 0.04) in
uPAR mRNA levels (Fig. 2D) in MDA-MB-231 cells even when
cultured in 20% O2. In contrast, compared with uPAR
expression in cells incubated in 20% O2 alone, no
significant increase in uPAR protein (p = 0.89) or
transcript (p = 0.35) levels was observed in cells
incubated with a combination of L-NMMA (0.5 mM)
and GTN (0.1 nM) in 20% O2 (Fig. 2,
B and D).
Effect of Hypoxia on sGC Signaling--
The results obtained using
the enzyme-linked immunosorbent assay for cGMP revealed that, compared
with cells incubated in 20% O2, MDA-MB-231 breast
carcinoma cells incubated in 0.5% O2 for 6 h in the
presence of 3-isobutyl-1-methylxanthine (500 µM) exhibited a 50% reduction in accumulated cGMP levels
(p < 0.002) (Fig.
3A). This effect of hypoxia on
cGMP levels was prevented by co-incubation with the NO-mimetic drug GTN
(1 µM).
Western blot analysis was conducted to determine the effects of hypoxia
on sGC protein levels. sGC is a heterodimeric protein consisting mainly
of an Role of sGC in the NO-mediated Inhibition of uPAR
Expression--
Fig. 4A shows
that, compared with incubation of cells under control conditions (20%
O2 alone), incubation of MDA-MB-231 cells for 24 h
with the selective sGC blocker ODQ (0.5 µM) resulted in a
2.7-fold increase (p < 0.05) in the levels of uPAR
mRNA (Fig. 4A). Although the presence of GTN (1 µM) prevented the hypoxic up-regulation of uPAR mRNA
expression, GTN was unable to block the effect of hypoxia when ODQ was
also present in the medium (Fig. 4A).
sGC is a heme-containing enzyme that requires ferrous iron for its
biosynthesis and activity. Therefore, to further assess the
participation of this enzyme in the regulation of uPAR expression by
the NO signaling pathway, we cultured MDA-MB-231 cells in the presence
of DFO (100 µM), an iron chelator and inhibitor of heme biosynthesis. The results showed that, in a manner similar to culture
under hypoxic conditions or after pharmacological inhibition of NO
synthase, culture in the presence of DFO resulted in a 4-fold increase
(p < 0.007) in the levels of uPAR mRNA (Figs.
4B and 5C). In contrast to hypoxia, the
effect of DFO on uPAR mRNA expression was not prevented by 1 µM GTN.
Furthermore, the up-regulation of uPAR mRNA and protein expression
by hypoxia was significantly reduced (p < 0.0001) in a dose-dependent manner (up to 100%) by the presence of
8-Br-cGMP (0.1-10 µM, 24 h), a non-hydrolyzable
analog of cGMP (Fig. 5, A and
B). Interestingly, the presence of 8-Br-cGMP (1 µM) also resulted in the complete inhibition
(p < 0.01) of the DFO-induced up-regulation of uPAR
mRNA expression (Fig. 5C). These results indicate that a
major component of the hypoxia- and DFO-mediated stimulation of uPAR
expression is the inhibition of sGC.
Role of PKG in the NO-mediated Inhibition of uPAR
Expression--
As indicated earlier, cGMP-mediated activation of PKG
is an important component of the NO signaling pathway. To further
elucidate the role of NO signaling in the regulation of uPAR
expression, MDA-MB-231 cells were incubated for 6 h with the PKG
inhibitor KT5823 (10 µM). Northern and Western blot
analyses revealed that selective inhibition of PKG, even in 20%
O2, resulted in a 1.8-fold increase (p < 0.05) in uPAR protein and mRNA expression (Fig. 6, A and B). These
results demonstrate that PKG activation by cGMP is necessary for the
inhibition of uPAR expression by NO.
Effect of 8-Br-cGMP on Hypoxia-induced Invasion--
Results from
the in vitro invasion assay using Matrigel as a substrate
for invasion revealed that, compared with the invasiveness of cells
incubated in 20% O2, hypoxia stimulated the invasiveness of MDA-MB-231 cells by 3.9-fold (p < 0.0001) (Fig.
7). This effect of hypoxia on
invasiveness was completely inhibited by the presence of various
concentrations of 8-Br-cGMP (0.1 µM to 1 mM)
(Fig. 7).
The major finding of this study is that NO signaling plays an
important role in the regulation of hypoxia-induced invasiveness of
human MDA-MB-231 breast carcinoma cells. Furthermore, our results strongly suggest that the mechanisms by which cells adapt to hypoxia and reduced NO activity involve convergent processes.
This study also presents a novel role for
cGMP-dependent signaling in the regulation of cellular
invasiveness. Specifically, it was shown that the NO-mediated
inhibition of uPAR expression is dependent on the sequential activation
of sGC and PKG. Furthermore, it was determined that the hypoxic
up-regulation of uPAR expression and the concomitant enhancement of the
in vitro invasiveness are associated with reduced levels of
sGC and PKG signaling. Because invasion of the extracellular matrix is
an essential component of the metastatic process, these results suggest
that perturbations in the cGMP-dependent signaling pathway
could lead to increases in metastatic potential.
Our results show that the effects of hypoxia on sGC activity and uPAR
expression can be prevented by low concentrations of GTN. These
findings point to a mechanism of oxygen sensing and gene regulation
whereby phenotypes are modified in response to a decrease in
NO-mediated signaling. As shown in Fig.
8, we propose that this phenomenon is due
to a reduction in endogenous NO synthesis. Molecular oxygen is
obligatory for the conversion of L-arginine into NO and
L-citrulline by the enzyme NO synthase (20). Indeed, exposure of cells to low levels of O2 (1-3%) inhibits NO
production by up to 90% (21). Due to the reduced NO levels associated
with hypoxia, there is a decrease in guanylyl cyclase activity and a
consequential reduction in cGMP levels (Fig. 8). Supporting this
concept, Taylor et al. (22) showed that culturing intestinal epithelial cells under hypoxic conditions (1% O2) results
in a significant decrease in basal and stimulated cGMP levels.
Here, we have similarly shown that low O2 levels
decrease cGMP generation. Furthermore, we have demonstrated that the
decrease in cGMP signaling is correlated with an enhancement of uPAR
expression as well as with increased invasiveness. To strengthen the
concept that uPAR expression is regulated through sGC activation, this
study showed that GTN was unable to inhibit uPAR expression when sGC
activity was directly blocked with either ODQ or DFO (Fig. 4).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

80 °C until used. Samples were subjected to
SDS-PAGE, and the resolved proteins were transferred onto an Immobilon-P membrane (Millipore Corp., Bedford, MA) using a wet transfer apparatus (Bio-Rad). The membranes were blocked overnight at
4 °C in a solution containing 1% phosphate-buffered saline and
0.01% Tween 20 (PBS-T) and 5% dry milk powder. The blots were subsequently incubated for 1.5 h with a monoclonal anti-uPAR
antibody (2 µg/ml; monoclonal antibody 3937, American Diagnostica
Inc., Greenwich, CT) or polyclonal anti-sGC antiserum (0.5 µg/ml;
Cayman Chemical Co., Inc., Ann Arbor, MI), followed by six 5-min washes with PBS-T. The membranes incubated with the anti-uPAR antibody were
incubated for 1 h with a horseradish peroxidase-labeled goat anti-mouse IgG secondary antibody (1:7500 dilution; Bio-Rad), and the
membranes incubated with the anti-sGC antibody were incubated for
1 h with horseradish peroxidase-conjugated goat anti-rabbit IgG
(1:15000 dilution; Vector Laboratories, Inc., Burlingame, CA).
Following six additional 5-min washes with PBS-T, secondary antibodies
were detected by enhanced chemiluminescence (Amersham Biosciences) and
exposure on Kodak X-Omat Blue film.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (13K):
[in a new window]
Fig. 1.
Effect of GTN and SNP on the hypoxic
up-regulation of in vitro invasion by MDA-MB-231
cells. NO-mimetic drugs were added to the cells at the beginning
of the 24-h assay, and the invasion index for each treatment was
calculated after counting the cells that penetrated the membrane.
Bars represent the mean normalized invasion indices ± S.D. *, significantly different from the invasion index of untreated
cells incubated in 20% O2 (n = 6).
p values are indicated under "Results."

View larger version (31K):
[in a new window]
Fig. 2.
uPAR expression in MDA-MB-231 breast cancer
cells. Shown are the results from Western blot analysis of uPAR
protein expression in cells incubated in 1% O2 in the
presence of various concentrations of GTN (n = 3)
(A) or in 20% O2 in the absence or presence of
the NO synthase antagonist L-NMMA (0.5 µM)
alone or in combination with GTN (0.1 nM)
(n = 6) (B). The effect of GTN (1 pM) on uPAR mRNA levels was also examined by Northern
blot analysis of cells cultured under conditions similar to those for
the Western blots (n = 3 and 6, respectively)
(C and D). In all cases, GTN was added at the
beginning of the 24-h incubation period. 18S rRNA was used to assess
uniformity of RNA loading in the Northern blots. Bars
represent the mean relative densities ± S.D. *, statistically
significant differences compared with control (20% O2)
values. All p values are indicated under
"Results."

View larger version (23K):
[in a new window]
Fig. 3.
Effect of hypoxia on sGC activity and
expression in MDA-MB-231 breast carcinoma cells. A,
total cellular cGMP accumulated in MDA-MB-231 breast carcinoma cells
cultured for 6 h in 20 or 0.5% O2 in the presence or
absence of GTN (1 µM). cGMP levels were measured and
normalized to total protein levels. Values represent mean accumulated
cGMP ± S.D. (n = 3). B, Western blot
analysis of sGC expression in cells incubated for 24 h in 20 or
0.5% O2 (n = 3). Bars represent
the mean densities ± S.D. *, statistically significant
differences compared with control (20% O2) density values.
p values for each condition are indicated under
"Results."
1- and a
1-subunit. Culture under
hypoxic conditions for 24 h resulted in a 44% decrease in the
levels of the
1-subunit (p < 0.0001).
In contrast, culture under hypoxic conditions resulted in a 2.3-fold
increase (p < 0.02) in the levels of the
1-subunit (Fig. 3B). Although the ratio of
the
1- and
1-subunits was altered during
hypoxia, the total amount of sGC was not significantly changed.

View larger version (39K):
[in a new window]
Fig. 4.
Effect of sGC disruption on the NO-mediated
inhibition of uPAR expression in MDA-MB-231 breast carcinoma
cells. A, Northern blot analysis of uPAR mRNA
expression in cells cultured for 24 h in 20 or 0.5%
O2 with or without GTN (1 µM) and the
selective sGC inhibitor ODQ (0.5 µM) (n = 5). B, Northern blot analysis of uPAR expression in cells
cultured for 24 h in the presence or absence of the heme disrupter
DFO (100 µM) alone or in combination with GTN (1 µM) (n = 5). Bars in both
A and B represent mean relative densities ± S.D. *, significantly different. p values for each condition
are indicated under "Results."

View larger version (31K):
[in a new window]
Fig. 5.
Effect of 8-Br-cGMP on hypoxia- and
DFO-induced uPAR expression in MDA-MB-231 breast carcinoma cells.
A, Northern blot analysis of uPAR expression in cells
cultured for 24 h in 20 or 0.5% O2 in the absence or
presence of various concentrations of 8-Br-cGMP (n = 3). B, Western blot analysis of uPAR protein in cells
cultured for 24 h in 20 or 0.5% O2 in the absence or
presence of various concentrations of 8-Br-cGMP (n = 9). C, Northern blot analysis of the uPAR transcript in
cells cultured for 24 h in the absence or presence of DFO (100 µM) alone or with 8-Br-cGMP (1 µM)
(n = 6). Bars in A-C represent
mean relative densities ± S.D. *, significantly different from
control (20% O2) values. All p values are
indicated under "Results."

View larger version (27K):
[in a new window]
Fig. 6.
Effect of PKG inhibition on uPAR expression
in MDA-MB-231 breast carcinoma cells. A, Northern blot
analysis of uPAR expression in cells cultured for 6 h in the
presence or absence of the PKG inhibitor KT5823 (10 µM)
(n = 6). B, Western blot analysis of uPAR
protein levels in cells cultured for 6 h in the presence or
absence of the PKG inhibitor KT5823 (10 µM)
(n = 6). Bars represent mean relative
densities ± S.D. *, significantly different from control (20%
O2) values. All p values are indicated under
"Results."

View larger version (15K):
[in a new window]
Fig. 7.
Effect of 8-Br-cGMP on the hypoxic
up-regulation of the in vitro invasiveness of
MDA-MB-231 breast carcinoma cells. Cells were allowed to invade a
reconstituted extracellular matrix for 24 h in 20 or 0.5%
O2 in the absence or presence of various concentrations of
8-Br-cGMP. The invasion index for each treatment was calculated after
counting the cells that penetrated the membrane. Values are presented
as the relative mean invasion indices ± S.D. *, significantly
different from the invasion index of the control (20% O2)
cells (n = 6). All p values are indicated
under "Results."
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (17K):
[in a new window]
Fig. 8.
Proposed model for the NO signaling pathway
leading to inhibition of uPAR expression and invasiveness.
Activation of sGC by NO leads to increased production of cGMP, which in
turn activates PKG. The latter phosphorylates target proteins and leads
to inhibition of uPAR expression and cellular invasiveness. The
components of the pathway following PKG activation specific to
inhibition of invasion remain to be elucidated. However, interference
with this pathway at the level of NO production (hypoxia, NO synthase
inhibition), sGC activation (ODQ, DFO), cGMP depletion
(phosphodiesterases), and PKG activation (KT5823) leads to increased
uPAR expression, cellular invasiveness, and possibly metastasis.
8-Br-cGMP can directly activate PKG and thereby lead to inhibition of
invasion.
Previous studies have shown that treatment with DFO results in cellular adaptive responses similar to those induced by hypoxia (13, 23-25). This has led to the hypothesis that a hemeprotein or changes in the redox status of cells are responsible for the adaptive responses to hypoxia (26). In the present study, the DFO-mediated up-regulation of uPAR expression was inhibited by 8-Br-cGMP (Fig. 5). This indicates that a major component of the DFO-mediated stimulation of uPAR expression is inhibition of guanylyl cyclase activity and that DFO does not interfere with signals acting downstream of guanylyl cyclase.
There are many potential targets that could be phosphorylated by PKG and therefore serve as downstream effectors in the NO signaling pathway. One possible mechanism by which PKG regulates cellular adaptations to changes in oxygenation involves a perturbation of the MAPK pathway. This pathway is activated by hypoxia (27), and studies have shown that NO can prevent the phosphorylation of ERK through a PKG-mediated interference of Ras/Raf (28). This concept is supported by the study of Mitani et al. (29), who showed that NO donors and cGMP-mimetic drugs reduce elastase expression by suppressing ERK phosphorylation. This leads to a subsequent reduction in the activation and DNA-binding capacity of AML1B (the transcription factor for elastase). It is possible that cGMP- dependent NO signaling similarly inhibits hypoxia-induced ERK phosphorylation, thereby decreasing the activation of the transcription factors responsible for the up-regulation of uPAR expression.
The promoter region of uPAR contains binding sites for transcription
factors such as AP-1, Sp1/3, and nuclear factor-
B (30). HIF-1 levels
may also contribute to the transcriptional activation of the uPAR gene,
as previous examination of the sequences upstream of the uPAR
initiation codon revealed the presence of potential HIF-1-binding sites
(31). It has also been shown that HIF-1 accumulation and
transcriptional activity can be reduced by relatively high
concentrations (2.5-500 µM) of NO-mimetic drugs such as
SNP, S-nitroso-L-glutathione, and
3-morpholinosydnonimine (12, 13). Preliminary studies in our laboratory
have confirmed that high concentrations (0.1-1 mM) of GTN
and SNP inhibit HIF-1 accumulation and transactivating activity.
The invasive potential of a cell is dependent upon its ability to break down components of the extracellular matrix and basement membranes. This process requires the participation of several proteolytic enzyme systems, among which the urokinase plasminogen activator system figures prominently (32). In vitro invasiveness has been strongly correlated with the levels of cell-surface uPAR expression (4, 33-35). For example, using an in vitro assay similar to the one in this study, Kariko et al. (33) showed that human osteosarcoma cells transfected with a human uPAR cDNA are four times more invasive than control cells. Xing and Rabbani (34) obtained similar results using a rat mammary carcinoma cell line. We have previously demonstrated that uPAR availability for urokinase plasminogen activator binding is essential for the hypoxic stimulation of invasiveness (4, 35). There is also clinical and experimental evidence that increased uPAR expression is associated with metastasis of prostate, colon, and breast carcinomas (34, 36, 37). Furthermore, using human melanoma cells transplanted into nude mice, Rofstad et al. (8) recently demonstrated that hypoxia-induced metastasis is dependent on uPAR up-regulation. Thus, we postulate that the cGMP-dependent inhibition of invasiveness observed in the present study was partially due to down-regulation of uPAR expression. Although the role of uPAR in invasion and tumor progression has been studied extensively, the mechanisms governing its expression are not fully understood. In characterizing the contribution of the plasminogen activator system to the regulation of invasiveness and metastasis, the present study confirmed that uPAR message and protein are up-regulated during hypoxia. In addition, we demonstrated that the NO signaling pathway involving sGC and PKG activation is an integral component of the mechanism that regulates uPAR expression as well as invasiveness.
In summary, this study specifically links NO-mediated activation of sGC
and PKG to the regulation of tumor cell invasiveness. Furthermore, our
results suggest that sGC and PKG may be useful pharmacological targets
for the prevention of cancer invasion and metastasis.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Shannyn MacDonald-Goodfellow, Lori Maxwell, and Judy Pang for technical assistance. We also thank Drs. S. Pang and J. Elce for helpful suggestions.
| |
FOOTNOTES |
|---|
* This work was supported in part by a grant from the Canadian Institutes of Health Research (to C. H. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Recipient of a joint studentship from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada.
Recipient of a postdoctoral fellowship from the Canadian
Hypertension Society.

Research Scholar from the Heart and Stroke Foundation of
Canada. To whom correspondence and reprint requests should be
addressed: Dept. of Anatomy and Cell Biology, Botterell Hall, Rm. 859, Queen's University, Kingston, Ontario K7L 3N6, Canada. Tel.:
613-533-2852; Fax: 613-533-2566; E-mail:
grahamc@post.queensu.ca.
Published, JBC Papers in Press, July 9, 2002, DOI 10.1074/jbc.M204529200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: uPAR, urokinase plasminogen activator receptor; HIF-1, hypoxia-inducible factor-1; sGC, soluble guanylyl cyclase; PKG, protein kinase G; GTN, glyceryl trinitrate; SNP, sodium nitroprusside; L-NMMA, N-monomethyl-L-arginine; DFO, desferrioxamine mesylate; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; Br, bromo; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Brown, J. M.
(1999)
Cancer Res.
59,
5863-5870 |
| 2. |
Matthews, N. E.,
Adams, M. A.,
Maxwell, L. R.,
Gofton, T. E.,
and Graham, C. H.
(2001)
J. Natl. Cancer Inst.
93,
1879-1885 |
| 3. | Teicher, B. A. (1998) Cancer Metastasis Rev. 13, 139-168 |
| 4. | Graham, C. H., Forsdike, J., Fitzgerald, C. F., and MacDonald-Goodfellow, S. (1999) Int. J. Cancer 80, 617-623[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Cuvier, C., Jang, A., and Hill, R. P. (1997) Clin. Exp. Metastasis 15, 19-25[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Young, S. D.,
Marshall, R. S.,
and Hill, R. P.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
9533-9537 |
| 7. |
Cairns, R. A.,
Kalliomaki, T.,
and Hill, R. P.
(2001)
Cancer Res.
61,
8903-8908 |
| 8. |
Rofstad, E. K.,
Rasmussen, H.,
Galappathi, K.,
Mathiesen, B.,
Nilsen, K.,
and Graff, B. A.
(2002)
Cancer Res.
62,
1847-1853 |
| 9. | Griffith, O. W., and Stuehr, D. J. (1995) Annu. Rev. Physiol. 57, 707-736[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Sciorati, C., Nistico, G., Meldolesi, J., and Clementi, E. (1997) Br. J. Pharmacol. 122, 687-697[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Sogawa, K.,
Numayama-Tsuruta, K.,
Ema, M.,
Abe, M.,
Abe, H.,
and Fujii-Kuriyama, Y.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7368-7373 |
| 12. |
Liu, Y.,
Christou, H.,
Morita, T.,
Laughner, E.,
Semenza, G. L.,
and Kourembanas, S.
(1998)
J. Biol. Chem.
273,
15257-15262 |
| 13. |
Huang, L. E.,
Willmore, W. G., Gu, J.,
Goldberg, M. A.,
and Bunn, H. F.
(1999)
J. Biol. Chem.
274,
9038-9044 |
| 14. | Denninger, J. W., and Marletta, M. A. (1999) Biochim. Biophys. Acta 1411, 334-350[Medline] [Order article via Infotrieve] |
| 15. | Nunokawa, Y., and Tanaka, S. (1992) Biochem. Biophys. Res. Commun. 188, 409-415[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Sogo, N., Magid, K. S., Shaw, C. A., Webb, D. J., and Megson, I. L. (2000) Biochem. Biophys. Res. Commun. 279, 412-419[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Forslund, T., Nilsson, H. M., and Sundqvist, T. (2000) Biochem. Biophys. Res. Commun. 274, 482-487[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Lincoln, T. M.,
Dey, N.,
and Sellak, H.
(2001)
J. Appl. Physiol.
91,
1421-1430 |
| 19. | Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. (1974) J. Natl. Cancer Inst. 53, 661-674[Medline] [Order article via Infotrieve] |
| 20. | Dweik, R. A., Laskowski, D., Abu-Soud, H. M., Kaneko, F., Hutte, R., Stuehr, D. J., and Erzurum, S. C. (1998) J. Clin. Invest. 101, 660-666[Medline] [Order article via Infotrieve] |
| 21. | Whorton, A. R., Simonds, D. B., and Piantadosi, C. A. (1997) Am. J. Physiol. 272, L1161-L1166[Medline] [Order article via Infotrieve] |
| 22. |
Taylor, C. T.,
Lisco, S. J.,
Awtrey, C. S.,
and Colgan, S. P.
(1998)
J. Pharmacol. Exp. Ther.
284,
568-575 |
| 23. | Gleadle, J. M., Ebert, B. L., Firth, J. D., and Ratcliffe, P. J. (1995) Am. J. Physiol. 268, C1362-C1368[Medline] [Order article via Infotrieve] |
| 24. |
Wang, G. L.,
and Semenza, G. L.
(1993)
Blood
82,
3610-3615 |
| 25. |
Goldberg, M. A.,
Dunning, S. P.,
and Bunn, H. F.
(1988)
Science
242,
1412-1415 |
| 26. | Ratcliffe, P. J., O'Rourke, J. F., Maxwell, P. H., and Pugh, C. W. (1998) J. Exp. Biol. 201, 1153-1162[Abstract] |
| 27. | Lo, L. W., Cheng, J. J., Chiu, J. J., Wung, B. S., Liu, Y. C., and Wang, D. L. (2001) J. Cell. Physiol. 188, 304-312[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Yu, S. M.,
Hung, L. M.,
and Lin, C. C.
(1997)
Circulation
95,
1269-1277 |
| 29. |
Mitani, Y.,
Zaidi, S. H.,
Dufourcq, P.,
Thompson, K.,
and Rabinovitch, M.
(2000)
FASEB J.
14,
805-814 |
| 30. | Wang, Y. (2001) Med. Res. Rev. 21, 146-170[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Graham, C. H.,
Fitzpatrick, T. E.,
and McCrae, K. R.
(1998)
Blood
91,
3300-3307 |
| 32. | Friedl, P., and Brocker, E. B. (2000) Cell. Mol. Life Sci. 57, 41-64[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Kariko, K.,
Kuo, A.,
Boyd, D.,
Okada, S. S.,
Cines, D. B.,
and Barnathan, E. S.
(1993)
Cancer Res.
53,
3109-3117 |
| 34. | Xing, R. H., and Rabbani, S. A. (1996) Int. J. Cancer 67, 423-429[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Graham, C. H., Postovit, L.-M., Park, H., Canning, M. T., and Fitzpatrick, T. E. (2000) Placenta 21, 443-450[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Crowley, C. W.,
Cohen, R. L.,
Lucas, B. K.,
Liu, G.,
Shuman, M. A.,
and Levinson, A. D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5021-5025 |
| 37. | Ganesh, S., Sier, C. F., Heerding, M. M., Griffioen, G., Lamers, C. B., and Verspaget, H. W. (1994) Lancet 344, 401-402[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
D. R. Siemens, N. Hu, A. K. Sheikhi, E. Chung, L. J. Frederiksen, H. Pross, and C. H. Graham Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide Cancer Res., June 15, 2008; 68(12): 4746 - 4753. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Frederiksen, R. Sullivan, L. R. Maxwell, S. K. Macdonald-Goodfellow, M. A. Adams, B. M. Bennett, D. R. Siemens, and C. H. Graham Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling Clin. Cancer Res., April 1, 2007; 13(7): 2199 - 2206. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Rofstad, B. Mathiesen, K. Kindem, and K. Galappathi Acidic Extracellular pH Promotes Experimental Metastasis of Human Melanoma Cells in Athymic Nude Mice. Cancer Res., July 1, 2006; 66(13): 6699 - 6707. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Frieboes, X. Zheng, C.-H. Sun, B. Tromberg, R. Gatenby, and V. Cristini An Integrated Computational/Experimental Model of Tumor Invasion Cancer Res., February 1, 2006; 66(3): 1597 - 1604. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Cristini, H. B. Frieboes, R. Gatenby, S. Caserta, M. Ferrari, and J. Sinek Morphologic Instability and Cancer Invasion Clin. Cancer Res., October 1, 2005; 11(19): 6772 - 6779. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. He, P. E. C. Brenchley, G. C. Jayson, L. Hampson, J. Davies, and I. N. Hampson Hypoxia Increases Heparanase-Dependent Tumor Cell Invasion, Which Can Be Inhibited by Antiheparanase Antibodies Cancer Res., June 1, 2004; 64(11): 3928 - 3933. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||